6/29/23, 1:34 AM PARTITA Pathway Feedback Search Clinical Topics Home Studies PARTITA PARTITA Disease Disease Dilated cardiomyopathy Ventricular arrhythmias Trial question What is the role of VT ablation in patients with an implantable cardioverter defibrillator? Study design Multi-center Open label RCT Population Characteristics of study participants 15.0% female N = 47 85.0% male 47 patients (7 female, 40 male) Inclusion criteria: patients with dilated cardiomyopathy who received implantable cardioverter defibrillator shock for VT Key exclusion criteria: contraindication to transcatheter ablation or antithrombotic therapy; chronic treatment with class I or class III antiarrhythmic drug Interventions N=23 ablation (VT ablation within 2 months of the implantable cardioverter defibrillator shock) N=24 standard therapy (continuation of standard therapy) Primary outcome Composite outcome of death from any cause or hospitalization for worsening heart failure https://web.pathway.md/studies/recUxIaM4ZCCvGJVr 1/2 6/29/23, 1:34 AM PARTITA Pathway 42.0 % 42 31.5 % 21.0 % Significant decrease 10.5 % NNT = 3 4 0.0 % Ablation Standard therapy Significant decrease in composite outcome of death from any cause or hospitalization for worsening HF (4% vs. 42%; HR 0.11, 95% CI 0.01 to 0.85) Secondary outcomes Significant decrease in death from all causes (ARD -33, 95% CI -55.44 to -10.56) Significant decrease in recurrent VT with shocks (9% vs. 42%; ARD -33, 95% CI -64.39 to -1.61) No significant difference in worsening HF hospitalization (4% vs. 17%; ARD -13, 95% CI -31.07 to 5.07) Conclusion In patients with dilated cardiomyopathy who received implantable cardioverter defibrillator shock for VT, ablation was superior to standard therapy with respect to the composite outcome of death from any cause or hospitalization for worsening HF. Reference Paolo Della Bella, Francesca Baratto, Pasquale Vergara et al. Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022 Jun 21;145(25):1829- 1838. Open reference URL https://web.pathway.md/studies/recUxIaM4ZCCvGJVr 2/2